Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow PASG by emailGet an email when PASG pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about PASG, unsubscribe in one click. Privacy
📣 What PASG Says Is Next
1Q 2027 · “Advancing clinical stage, potential best-in-class, one-time progranulin raising gene therapy for FTD Pursuing preclinical development of differentiated gene therapy approach in Huntington’s disease Cash runway expected through 1Q 2027* Validating the Therapeutic Potential of PBFT02 4 April 2026 * Based on interim data.”
Company press release, Apr 20, 2026 · SEC filing
1Q 2027 · “Advancing clinical stage, potential best-in-class, one-time progranulin raising gene therapy for FTD Pursuing preclinical development of differentiated gene therapy approach in Huntington’s disease Cash runway expected through 1Q 2027* Validating the Therapeutic Potential of PBFT02 4 March 2026 * Based on interim data.”
Company press release, Mar 3, 2026 · SEC filing
1Q 2027 · “Advancing clinical stage, potential best - in - class, one - time progranulin raising gene therapy for FTD Pursuing preclinical development of differentiated gene therapy approach in Huntington’s disease Cash runway expected into 1Q 2027* Validating the Therapeutic Potential of PBFT02 January 2026 4 * Based on interim data.”
Company press release, Jan 12, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full PASG picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for PASG and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.